Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alteplase and conbercept combination
- Development stage
- Unknown
- Lead developer
- Chengdu Kanghong Pharmaceutical
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subretinal, Intravitreal
01
Overview
The combination of alteplase (recombinant tissue plasminogen activator or rt-PA) and conbercept represents a therapeutic approach used primarily for treating submacular hemorrhage (SMH). This combination therapy involves pars plana vitrectomy (PPV) with subretinal injection of low-dose alteplase and intravitreal injection of conbercept. Alteplase functions as a thrombolytic agent, working by cleaving plasminogen to form plasmin, an enzyme that degrades fibrin clots, thereby helping to dissolve the blood clot. Conbercept is an anti-VEGF (vascular endothelial growth factor) agent. The combination therapy shows promise in enhancing both vision and anatomical structure in submacular hemorrhage treatment.
- Other names
- alteplase + conbercept
02
Targets
Fibrin-bound plasminogenVEGFA (Vascular endothelial growth factor A)PGF (Placental Growth Factor)VEGFC (VEGF-C)VEGFB (Vascular endothelial growth factor B)Fibrin (Factor Ia)
Beyond the preview
Go deeper on alteplase and conbercept combination.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alteplase and conbercept combination.